Take Part in Research
See below for opportunities to take part in psoriasis research, or to share your experiences. Please note that these projects are not run by the Psoriasis Association, but by external parties such as academic research departments.
We do not normally advertise commercial clinical trials. If the opportunities below do not match the type of project you are looking to be involved in, you can also take a look at 'Be Part of Research', which is run by the National Institute for Health Research (NIHR) and will give you lots of information about taking part in clinical trials and allow you to search for a relevant trial in your area. More information about clinical trials can also be found on the NHS website and at ClinicalTrials.gov.
JAKPPPOT Trial - participants still needed
PLEASE NOTE: If you previously expressed an interest in taking part in this trial, but have not yet been contacted by the JAKPPPOT team, please email gstt.JAKPPPOT@nhs.net.
We are aware that potential participants have not been receiving emails from the above address - so please make sure to check your spam/junk folders.
The JAKPPPOT team are still seeking participants with palmoplantar pustulosis, diagnosed by a dermatologist.
During the trial, participants will take a tablet once-a-day for 8 weeks. This tablet will be a janus kinase inhibitor, a new group of drugs that suppresses the immune system. The drug is called upadacitinib (its brand name is ‘Rinvoq’).
Participants will attend our clinic at Guy’s and St Thomas’s NHS Trust, London Bridge, regularly during the 8-week trial, and we will take blood samples at each visit. We will also invite participants to take part in a voluntary interview before and after the 8 weeks of treatment to understand their thoughts on the tablet and the trial more generally.
Participants will need to be over the age of 18, and cannot be pregnant or breast-feeding. Participants will need to stop all UV light related treatment or systemic treatment (medications taken by mouth or injected) that they are currently taking, but they can continue using certain topical treatments (creams/ointments).
Please
contact Dr David Gleeson (Principal Investigator) at gstt.JAKPPPOT@nhs.net to find out more about this study.
Patient-Reported Outcome Measures Platform - Healthcare Improvement Scotland (SCOTLAND ONLY)
Healthcare Improvement Scotland is currently developing a new NHS Scotland digital system to help patients tell their healthcare team how they feel and how their treatment is going. This will be called the Patient-Reported Outcome Measures (PROMs) Platform, and it will be used by healthcare teams to send questionnaires to their patients.
We’re looking for volunteers to attend a 1-hour focus group to tell us what you think of proposals for this new system. We will show you live examples of how it could work and then ask for your opinions. These sessions will run in late February, with options to attend either in-person in Glasgow or via Microsoft Teams.
If you are living in Scotland, and you would be interested in participating in this work, please complete this short form with your availability:
Participation Form - Development of a new digital service for patients
If you are unable to complete the form or if you have any questions, please get in touch with us at his.decisionsupport@nhs.scot.
Share your experiences with a long-term skin condition to help improve care and support
An upcoming University of Brighton study is seeking people with long-term skin conditions to share their experiences and help to improve care and support.
By sharing your story, your perspective will contribute to continued research and help to shape future services for people with skin conditions.
If you meet all of the following criteria and are interested in finding out more, please contact c.lubinska1@uni.brighton.ac.uk:
- Must be aged 18 and over
- Must be diagnosed with a chronic skin condition
- Must be undergoing, or have previously received treatment
- Must be symptomatic for over a year
- Must be living in the UK.
FaceIT - using online support tools to manage appearance-related concerns
The University of Plymouth and the University of the West of England, Bristol are seeking participants for a study into how online support tools can help to manage appearance-related concerns.
If you or a loved one with have an altered or different appearance, you are eligible to take part in the FaceIT@home study – a free to use online tool to support individuals with visible differences.
FaceIT can be accessed flexibly – users can access the tool independently, or with a health professional. For health professionals supporting people with visible differences, the tool can be integrated into existing client support services.
To find out more about the study, you can visit the FaceIT website or email faceitathome@gmail.com.
RMD-Health machine-learning based tool
Researchers at the University of Reading are developing a machine-learning based tool to help ensure that the right patients with rheumatic and musculoskeletal diseases see the right doctor to treat their conditions.
The research team is seeking people living with rheumatic and musculoskeletal disease to join the RMD-Health Patient and Public Advisory Group (PPAG).
What does participation require?
If you are selected as a member of the RMD-Health PPAG, you will be asked to prepare for, attend and actively participate in 4 x 90-minute-long meetings.
Members are asked to commit to their role until the project ends on 30th September 2027.
Members of the RMD-Health PPAG will be paid at a rate of £75 per regular PPAG meeting (to include preparation and follow-up).
Who can participate?
The research team is looking for participants who:
● Have had direct or indirect experience of rheumatic and musculoskeletal diseases.
● Are able to contribute to meetings that may involve up to 10 people.
● Have the ability and willingness to join meetings via Microsoft Teams.
How can I apply?
Please send your expression of interest, outlining why you would like to join the group
to julie.hart@henley.ac.uk by 27th March 2026.
Developing a social media intervention to increase awareness and understanding of psoriasis: A mixed-methods project using co-production with adults with psoriasis
Do you live with psoriasis and use social media? We want to hear from you!
We're recruiting for an exciting research study exploring the experiences of people living with psoriasis and the social media content around psoriasis.
You could help shape better support and awareness for the psoriasis community.
How to get involved
Get involved by completing the survey linked here.
Research contact:
Mani: emmanuel.toni@uwe.ac.uk
Instagram Live Q&A Recap
The Psoriasis Association hosted an Instagram Live Q&A with Mani, Dermatology ANP, to answer your questions about getting involved in the study.
You can watch a recap in the video below, or click this link to watch the video on YouTube.
MOVE SMART for Psoriasis
We want to find out if MOVE SMART, new lifestyle programme for patients with psoriasis, can help psoriasis and other conditions linked with psoriasis. MOVE SMART has been developed by dermatologists, scientists and patients with psoriasis and can be followed from your home or workplace.
The study involves:
- All participants following MOVE SMART (half during the first 12-weeks and half after 24-weeks).
- No appointments at the Research Centre. This study can be followed from your home or workplace.
- Contact with the research group throughout the study.
- Completing questionnaires about your psoriasis, general health and what you like / dislike about the study.
- Aged between 18 and 60
- Psoriasis that started before the age of 40
- Some psoriasis on their skin
- Psoriatic arthritis (and those who do not have psoriatic arthritis)
- Unable to rise from sitting to standing and walk around a room (independently or aided by a stick or trolly) at a steady pace
- Pregnant or breastfeeding
- Severe heart or chest problems
- Already following physical activity guidelines
We are looking for people who are/have:
This study is not suitable for people who have / are:
How to Get Involved
You will receive a gift voucher as a thank-you for your time.
HPOS trial to identify who might develop psoriatic arthritis
How to get involved
Taking part is simple. Participants, who are over 18 years of age and diagnosed with psoriasis, but not with psoriatic arthritis, will be asked to complete an online questionnaire every 6 months.
Over a period of 3 years, the responses will be monitored and from the results the researchers will be able to identify which patients will go on to develop arthritis. The long-term aim is to try to prevent the development of arthritis before it occurs.
Please help and sign up at this link: https://www.hpos.study/
Make A Difference
Take a look at the video below to learn more about the study, or click this link to watch the video on YouTube.
Opportunity for adolescent patients with psoriasis to take part in a trial comparing Risankizumab with Ustekinumab (OptIMMize-1)
***UPDATE - Please note that Parts 1, 2 and 3 of this study are now closed to recruitment. Recruitment for Part 4 of the study has not yet commenced – details will be announced in due course.***
This is an opportunity for 12-17 year old patients with moderate to severe plaque psoriasis. The trial, sponsored by the pharmaceutical company, AbbVie, compares the treatment efficacy and safety of Risankizumab (Skyrizi) vs Ustekinumab (Stelara), two biologic therapies. All participants are guaranteed active treatment, regardless of whether they have had systemic therapy before.
Recruitment criteria (list not exclusive):
- Aged between 12 to < 18 years at the time of enrolment
- Have had a diagnosis of chronic plaque psoriasis for at least 6 months
- Have moderate to severe psoriasis, defined as ≥ 10% Body Surface Area (BSA) psoriasis involvement with a static Physician’s Global Assessment (sPGA) score of ≥ 3, or Psoriasis Area and Severity Index (PASI) ≥ 12
- Erythrodermic psoriasis, generalised or localised pustular psoriasis, medication-induced or medication exacerbated psoriasis, or new onset guttate psoriasis;
- Active skin disease other than psoriasis that could interfere with the assessment of psoriasis;
- Clinically significant drug or alcohol abuse within the last 6 months;
- An allergic reaction or hypersensitivity to a biologic agent or its excipients;
- A latex allergy;
- An organ transplant that requires continued immunosuppression;
- Any malignancy except for successfully treated non-melanoma skin cancer or localised carcinoma in situ of the cervix.
- Hepatitis B (HB) (hepatitis B virus [HBV]) or hepatitis C (hepatitis C virus [HCV]) infection;
- Human immunodeficiency virus (HIV), defined as confirmed positive anti-HIV antibody (HIV Ab) test;
- Genetic deficiency in IL-12/IL-23;
- West Ambulatory Care Hospital, Glasgow: Areti.Makrygeorgou@ggc.scot.nhs.uk
- Frimley Park Hospital, Surrey: sara.sherif@nhs.net
- Royal Devon and Exeter Hospital, Devon: naomi.goldstraw@nhs.net
- Derriford Hospital, Plymouth: thurein.newin@nhs.net
- Guy’s and St Thomas’ NHS Foundation Trust, London: please email Eva.Hilger@gstt.nhs.uk or call 07917217601
No history of:
No evidence of:
The following centres are
open for recruitment into the study (please email the investigators directly):
Dr Wedad Abdelrahman,
Chief Investigator
(wedad.abdelrahman@gstt.nhs.uk)
Prof Carsten Flohr,
Study Investigator (carsten.flohr@kcl.ac.uk)
Consultant Paediatric Dermatologists
St John’s Institute of
Dermatology,
Guy’s & St Thomas’
NHS Foundation Trust